naa a22 4500 510785638 CHVBK 20180411083301.0 cr unu---uuuuu 180411e20130101xx s 000 0 eng 10.1007/s12603-013-0002-2 doi (NATIONALLICENCE)springer-10.1007/s12603-013-0002-2 2012: A watershed year for Alzheimer's disease research [Elektronische Daten] [M. Grundman, A. Dibernardo, N. Raghavan, M. Krams, E. Yuen] Despite negative topline phase 3 clinical trial results for bapineuzumab and solanezumab in mild to moderate AD, findings from these trials and recent advances suggest renewed optimism for anti-amyloid therapies. Aβ immunotherapy has now demonstrated its ability to engage CNS Aβ and modify downstream CNS biomarkers in bapineuzumab treated patients, and to show likely cognitive benefits in mild patients treated with solanezumab. The current availability of potent BACE inhibitors provides additional opportunities to test the value of reducing Aβ in the clinic. Trial enhancements, such as selecting and enriching for early stage AD, treating participants longer and using more sensitive composite endpoints may further improve our chances of demonstrating clinical efficacy and securing beneficial treatments for patients. Serdi and Springer-Verlag France, 2013 Alzheimer's disease nationallicence bapineuzumab nationallicence solanezumab nationallicence BACE nationallicence beta-amyloid nationallicence disease modification nationallicence composite endpoints nationallicence Grundman M. Global R&D Partners, LLC, San Diego, CA, USA aut Dibernardo A. Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, New Jersey, USA aut Raghavan N. Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, New Jersey, USA aut Krams M. Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, New Jersey, USA aut Yuen E. Janssen Alzheimer Immunotherapy R&D, LLC, South San Francisco, CA, USA aut The journal of nutrition, health & aging Springer-Verlag 17/1(2013-01-01), 51-53 1279-7707 17:1<51 2013 17 12603 https://doi.org/10.1007/s12603-013-0002-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12603-013-0002-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Grundman M. Global R&D Partners, LLC, San Diego, CA, USA aut NATIONALLICENCE 700 1- Dibernardo A. Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, New Jersey, USA aut NATIONALLICENCE 700 1- Raghavan N. Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, New Jersey, USA aut NATIONALLICENCE 700 1- Krams M. Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, New Jersey, USA aut NATIONALLICENCE 700 1- Yuen E. Janssen Alzheimer Immunotherapy R&D, LLC, South San Francisco, CA, USA aut NATIONALLICENCE 773 0- The journal of nutrition, health & aging Springer-Verlag 17/1(2013-01-01), 51-53 1279-7707 17:1<51 2013 17 12603 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer